Phase 4 N=98 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Symptomatic Orthostatic Hypotension
Primary: Percent of Subjects Who Failed to Maintain a Response — 30.3; 44.1 percentage of participants — p=0.3145
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction
Hypersensitivity
Primary: Tooth Hypersensitity to Touch Stimuli (Tactile) — 10.83; 10.63 Units on a scale — p=0.05
Phase 3 N=102 Compare the Clinical Efficacy of Prototype Toothpastes
Dental Plaque
Primary: Plaque Index — 0.91; 0.84; 1.77 Units on a scale — p=0.05
Phase 2 N=205 A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
Rosacea
Primary: Investigator Global Assessment (IGA) 0=Clear, 1=Near Clear, 2=Mild, 3=Moderate, 4=Severe — 35; 15; 16; 6 Participants
Phase 3 N=113 Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
Dentine Hypersensitivity
Primary: Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14 — -1.20; -0.37 Score on a scale — p=<0.0001
Phase 3 N=1,946 In Vivo Efficacy Study of Patient Preoperative Preps
Bacterial Reduction Post-product Application
Primary: Responder Rate — 159; 165; 163; 5 Participants — p=<0.0001
Phase 3 N=440 In-vivo Efficacy of Patient Preoperative Prep
Surgical Skin Preparation
Primary: Bacterial Reduction — 4.83; 4.78; 2.23 log10 CFU/cm^2
Phase 3 N=1,761 Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal
Influenza
Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Regardless of Vaccine Match) — 17.9; 18.0 percentage of participants — p=0.996
Phase 3 N=103 Compare the Clinical Efficacy of Prototype Toothpastes.
Gingival Diseases
Primary: Dental Plaque — 2.273; 1.806; 2.041 Units on a scale — p=<0.05
Phase 3 N=244 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Mucosal Healing and No Deep Ulcerations — 30.3; 45.9 percentage of participants — p=0.010
Phase 2 N=269 Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9) — 37; 20 Participants
N/A N=381 Efficacy and Tolerability of Venoactive Drugs in Patients With Chronic Venous Diseases C4a&b in Real Clinical Practice.
Chronic Venous Diseases
Primary: The Mean Subcutaneous Adipose Tissue Thickness Changes (mm) Between the Visit 3 and Baseline by Ultrasound Examination. — 2.5 mm
Phase 3 N=911 Clinical Endpoint Study of Ivermectin 0.5% Lotion
Head Lice
Primary: Percentage of Index Participants Who Were Considered a Treatment Success: PP Population — 90.9; 89.0 percentage of participants
Phase 2 N=41 Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
N/A N=13 ASSURE WCD Clinical Evaluation - Conversion Efficacy Study
Death, Sudden, Cardiac
Primary: Cumulative First and Second Shock VT/VF Conversion Rate — 100; 100 percentage
N/A N=3,130 Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
Tracheitis · Tracheobronchitis · Bronchitis
Primary: Disappearance or Significant Alleviation of Symptoms — 3109 Participants
Phase 3 N=609 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
Clostridium Difficile Infection
Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 81; 85.7 Percentage of participants
Phase 3 N=632 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
Clostridium Difficile Infection
Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 83.8; 85.2 Percentage of participants
Phase 2 N=60 Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP
Gingivitis · Periodontitis
Primary: Changes in Modified Gingival Index (MGI) — 8.5; 1.5 score on a scale — p=<0.001
Phase 3 N=68 Clinical Performance of a Chlorhexidine Antimicrobial Dressing
Catheterization
Primary: Clinician Overall Satisfaction With Catheter Securement — 2.27; 1.63 Units on a scale
Phase 3 N=475 Demonstrate Efficacy and Safety of Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate — 138; 143 Participants
Phase 3 N=904 Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks — -0.009; 0.142; 0.156; 0.168 Liter — p=<0.0001
N/A N=773 Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.
Urinary Tract Infection Complicated · Urinary Tract Infection (cUTI) · Urinary Tract Infection (Diagnosis)
Primary: Favorable Clinical Outcomes (FCl) — 170; 132 Participants
N/A N=100 Efficacy of an Antibacterial Toothpaste and Patients' Satisfaction
Caries · Gingivitis
Primary: Bacterial Count of Streptococcus Mutans (S. Mutans) — 4.261; 4.277 log CFU/ml
N/A N=256 Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
Multiple Sclerosis
Primary: Change in Annualized Relapse Rate (ARR) Between the Pre-Baseline 12-Month Period (Baseline) and Over the 12 Months Period Before the End of Study Follow-Up (2 Years)…
Phase 3 N=286 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.
Purulent Bacterial Conjunctivitis
Primary: The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3 — 48; 29 participants
Phase 1 N=879 Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Asthma
Primary: Area Under the Serial FEV1-time Curve (AUC 0-12h) — 29.610; 30.151; 27.270 Liters — p=<0.05
Phase 3 N=25 Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.
Gingival Diseases
Primary: Plaque Index — 2.45; 2.22; 2.54; 2.56 Units on a scale — p=0.05
Phase 4 N=1,206 Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
Human Immunodeficiency Virus
Primary: LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death — 47; 39 participants — p=0.59
Phase 2 N=294 Efficacy Study in Patients With Acne Vulgaris.
Acne Vulgaris
Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947